|

Cetuximab Clinical Trials

76 actively recruiting trials across 27 locations

▼ -8 trials since May 2026

Also known as: C 225, C-225, C225, Cetuximab Antibody, Cetuximab Biosimilar CDP-1 +13 more

Pipeline

Phase 1: 31Phase 2: 20Phase 3: 11Phase 1/2: 12Phase 2/3: 1

Top Sponsors

  • Merck Sharp & Dohme LLC6
  • M.D. Anderson Cancer Center6
  • National Cancer Institute (NCI)3
  • Fudan University3
  • University of Chicago2

Indications

  • Cancer76
  • Lung Cancer18
  • Colorectal Cancer11
  • Non Small Cell Lung Cancer7
  • Metastatic Colorectal Cancer6

Other21 trials

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Phase 2
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/2
A Study of BND-35 in Participants With Advanced Solid Tumors
Phase 1
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
Phase 1/2
AK129 Combination Therapy for Advanced Solid Tumors
Phase 1/2
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
Phase 1
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
Phase 2
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Phase 2
Combination Therapy for BRAF-V600E Metastatic CRCm
Phase 2
Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
Phase 2
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
Phase 1
Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA
Phase 2
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Phase 2
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
Phase 3
Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer
Phase 3
SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer
Phase 2
Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB
Phase 3
Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Phase 2
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
Phase 2
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
Phase 2

Los Angeles, California5 trials

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Los Angeles Hematology Oncology Medical Group ( Site 0084)

Phase 3
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Usc Norris Comprehensive Cancer Center (Nccc)

Phase 1
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Cedars-Sinai Medical Center

Phase 1/2
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

The Angeles Clinic and Research Institute

Phase 1
BBO-11818 in Adult Subjects With KRAS Mutant Cancer

The Angeles Clinic and Research Institute - West Los Angeles Office

Phase 1

Houston, Texas5 trials

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

MD Anderson Cancer Center

Phase 2
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

MD Anderson Cancer Center

Phase 1
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

MD Anderson Cancer Center

Phase 1/2
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

M D Anderson Cancer Center

Phase 1
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

MD Anderson Cancer Center

Phase 2

Birmingham, Alabama4 trials

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

UAB Comprehensive Cancer Center

Phase 1
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

University of Alabama at Birmingham

Phase 3
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

University of Alabama at Birmingham Cancer Center

Phase 2/3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

University of Alabama at Birmingham Cancer Center

Phase 3

Gilbert, Arizona4 trials

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Banner MD Anderson Cancer Center

Phase 3
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Banner MD Anderson Cancer Center

Phase 3
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Banner MD Anderson Cancer Center

Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Banner Health- MD Anderson Cancer Center

Phase 1/2

Phoenix, Arizona4 trials

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Local Institution - 0005

Phase 2
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Mayo Clinic Hospital

Phase 1
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Mayo Clinic, Phoenix

Phase 1
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

Mayo Clinic - Cancer Center - Phoenix

Phase 1

Duarte, California4 trials

A Study of ASP3082 in Adults With Advanced Solid Tumors

City of Hope National Medical Center

Phase 1
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

City of Hope Medical Center

Phase 1
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

City of Hope

Phase 1

Boston, Massachusetts3 trials

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Massachusetts General Hospital Cancer Center

Phase 1/2
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

Dana-Farber/Massachusetts General Hospital, Inc

Phase 1
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Brigham and Women's Hospital

Phase 2

Chandler, Arizona2 trials

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Ironwood Cancer and Research Center

Phase 3
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Ironwood Cancer and Research Centers

Phase 1/2

Clermont, Florida2 trials

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

Clermont Oncology Center ( Site 0041)

Phase 1/2
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Clermont Oncology Center ( Site 0041)

Phase 2

Chicago, Illinois2 trials

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

University of Chicago Medicine Comprehensive Cancer Center

Phase 1
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

University of Chicago Medicine Comprehensive Cancer Center

Phase 1

Baltimore, Maryland2 trials

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

Greater Baltimore Medical Center ( Site 1104)

Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Johns Hopkins Hospital

Phase 1/2

Grand Rapids, Michigan2 trials

Study of AUBE00 in Patients With Solid Tumors

South Texas Accelerated Research Therapeutics (START) Midwest

Phase 1
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

START Midwest

Phase 1

Basking Ridge, New Jersey2 trials

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Phase 2

Glendale, Arizona1 trial

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Palo Verde Hematology Oncology

Phase 3

Tucson, Arizona1 trial

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Arizona Oncology Associates

Phase 1

Fayetteville, Arkansas1 trial

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Highlands Oncology Group

Phase 1

Little Rock, Arkansas1 trial

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

University of Arkansas for Medical Sciences

Phase 3

La Jolla, California1 trial

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

University of Southern California

Phase 1

Orange, California1 trial

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

D3 Bio Investigative Site 0402

Phase 1/2

Stanford, California1 trial

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

GSK Investigational Site

Phase 1

Newark, Delaware1 trial

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Christiana Care Health System- Site Number : 8400011

Phase 1/2

Orlando, Florida1 trial

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Research Site

Phase 1

Tampa, Florida1 trial

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Moffitt Cancer Center ( Site 0261)

Phase 1

Bethesda, Maryland1 trial

FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

National Institutes of Health Clinical Center

Phase 1

New Brunswick, New Jersey1 trial

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

Rutgers Cancer Institute of New Jersey ( Site 0052)

Phase 1

Winston-Salem, North Carolina1 trial

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Wake Forest Baptist Comprehensive Cancer Center

Phase 2

Pittsburgh, Pennsylvania1 trial

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

UPMC Hillman Cancer Center - Radiation Oncology

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.